Skip to main content
Article thumbnail
Location of Repository

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

By O. Khan, M. Ranson, M. Michael, I. Olver, N. Levitt, P. Mortimer, A. Watson, G. Margison, R. Midgley and M. Middleton


To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5 consecutive days every 4 weeks in patients with metastatic colorectal carcinoma. Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40 mg) and TMZ (50–200 mg m−2) orally for 5 consecutive days every 4 weeks. Response was determined every two cycles. Pharmacokinetics of lomeguatrib and TMZ as well as their pharmacodynamic effects in peripheral blood mononuclear cells (PBMC) were determined. Nineteen patients received 49 cycles of treatments. Despite consistent depletion of O6-methylguanine-DNA methyltransferase in PBMC, none of the patients responded to treatment. Three patients had stable disease, one for the duration of the study, and no fall in carcinoembryonic antigen was observed in any patient. Median time to progression was 50 days. The commonest adverse effects were gastrointestinal and haematological and these were comparable to those of TMZ when given alone. This combination of lomeguatrib and TMZ is not efficacious in metastatic colorectal cancer. If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated.O. A. Khan, M. Ranson, M. Michael, I. Olver, N. C. Levitt, P. Mortimer, A. J. Watson, G. P. Margison, R. Midgley and M. R. Middleto

Topics: O⁶-methylguanine-DNA methyltransferase; lomeguatrib; temozolomide; colorectal cancer; DNA repair
Publisher: Nature Publishing Group
Year: 2008
DOI identifier: 10.1038/sj.bjc.6604366
OAI identifier:

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.